Topical liquid crystalline gel containing lornoxicam/cyclodextrin complex

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 73, Issue 1-4, 2012, Pages 161-175

  Ammar, H O ^a   Ghorab, M ^b   Mahmoud, A A ^a   Makram, T S ^c   Noshi, S H ^d  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c OCTOBER 6 UNIVERSITY   (Egypt)

^d October University for Modern Sciences and Arts   (Egypt)

Author keywords

Burn; Complexation; Cyclodextrin; Dissolution; Liquid crystalline gel; Lornoxicam; Physiochemical characterization; Topical

Indexed keywords

EID: 84862598984     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-011-0039-y     Document Type: Article

References (75)

1. Madigan, M.T., Martinko, M., Parter, J.: Microbial growth control. In: Brock, T.D. (ed.) Brock Biology of Microorganisms, 9th edn. Prentice Hill Inc, USA (2000)
2. Fur, J.R.: Fundamentals of immunology. In: Hugo, W.B., Russell, A.D. (eds.) Pharmaceutical Microbiology, 5th edn, pp. 305-331. Blackwell Scientific Publications, London (1992)
3. Inflammation. Available from: http://en.wikipedia.org/wiki/Inflammation (2010). Accessed 30 July 2010
4. HM Gloster DG Brodland 1996 The epidemiology of skin cancer Dermatol. Surg. 22 217 226 10.1016/1076-0512(95)00570-6
5. E Maverakis Y Miyamura MP Bowen G Correa Y Ono H Goodarzi 2010 Light, including ultraviolet J. Autoimmun. 34 247 257 10.1016/j.jaut.2009.11.011
6. Foye, W.O., Thomas, L.L., David, A.W.: Principles of Medicinal Chemistry, 4th edn, p. 335. Williams and Wilkins, USA (1995)
7. HW Lim GJ Thorbecke RL Baer 1983 Effect of indomethacin on alteration of ATPase-positive Langerhans cell density and cutaneous sunburn reaction induced by ultraviolet-B radiation J. Invest. Dermatol. 81 455 458 10.1111/1523-1747. ep12522659 1:CAS:528:DyaL3sXlvFSks7g%3D
8. DL Bissett R Chatterjee DP Hannon 1990 Photoprotective effect of topical anti-inflammatory agents against ultraviolet radiation-induced chronic skin damage in the hairless mouse Photodermatol. Photoimmunol. Photomed. 7 153 158 1:CAS:528:DyaK3MXhvVWgsLc%3D
9. SE Norholt S Sindet-Pedersen U Larsen U Bang J Ingerslev O Nielsen HJ Hansen AK Ersboll 1996 Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine Pain 67 335 343 10.1016/0304-3959(96)03126-0 1:STN:280:DyaK2s7gvFKntQ%3D%3D
10. H Staunstrup J Ovesen UT Laesrn K Elbaek U Larsen K Kroner 1999 Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain J. Clin. Pharmacol. 39 834 841 10.1177/00912709922008362 1:CAS:528:DC%2BD3cXivFWqsw%3D%3D
11. T Loftsson P Jarho M Masson T Jarvinen 2005 Cyclodextrins in drug delivery Expert. Opin. Drug Deliv. 2 335 351 10.1517/17425247.2.1.335 1:CAS:528:DC%2BD2MXjsFantrY%3D
12. A Magnúsdóttir M Másson T Loftsson 2002 Self association and cyclodextrin solubilization of NSAIDs J. Incl. Phenom. Macroc. Chem. Pharm. Bull. 44 213 218 10.1023/A:1023079322024
13. S Muňoz-Botella B Del Castillo M Martín 1995 Cyclodetrin properties and applications of inclusion complex formation Ars. Pharm. 36 187 198
14. T Loftssona T Jarvinen 1999 Cyclodextrins in ophthalmic drug delivery Adv. Drug Deliv. Rev. 36 59 79 10.1016/S0169-409X(98)00055-6 1:CAS:528:DyaK1MXksFegug%3D%3D
15. J Pitha J Milecki H Fales L Pannell K Uekama 1986 Hydroxypropyl-β- cyclodextrin preparation and characterization: effects on solubility of drugs Int. J. Pharm. 29 73 82 10.1016/0378-5173(86)90201-2 1:CAS:528: DyaL28XhvFejsbY%3D
16. T Loftsson ME Brewster 1996 Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 1017 1025 10.1021/js950534b 1:CAS:528:DyaK28XlsFSrsr4%3D
17. T Irie K Uekama 1997 Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation J. Pharm. Sci. 86 147 162 10.1021/js960213f 1:CAS:528:DyaK2sXhtVOgsLY%3D
18. DO Thompson 1997 Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals Crit. Rev. Ther. Drug.. Carr. Syst. 14 1 104 1:CAS:528:DyaK2sXhtlems7g%3D
19. S Gould RC Scott 2005 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review Food Chem. Toxicol. 43 1451 1459 10.1016/j.fct.2005.03.007 1:CAS:528:DC%2BD2MXmt1eiu78%3D
20. Brewster, M.E., Mackie, C., Lampo, A., Noppe, M., Loftsson, T.: The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines. In: Augustijns, P., Brewster, M.E. (eds.) Solvent Systems and their Selection in Pharmaceutics and Biopharmaceutics, pp. 221-256. American Association of Pharmaceutical Scientists and Springer, New York (2007)
21. RA Rajewski VJ Stella 1996 Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery J. Pharm. Sci. 85 1142 1169 10.1021/js960075u 1:CAS:528:DyaK28XmtFKgu70%3D
22. NM Skjodt NM Davies 1998 Clinical pharmacokinetics of lornoxicam. A short half-life oxicam Clin. Pharmacokinet. 34 421 428 10.2165/00003088-199834060- 00001 1:CAS:528:DyaK1cXkt1eisr0%3D
23. SZ Lin D Wouessidjewe MC Poelman D Duchene 1994 In vivo evaluation of indomethacin/cyclodextrin complexes. Gastrointestinal tolerance and dermal anti-inflammatory activity Int. J. Pharm. 106 63 67 10.1016/0378-5173(94)90276-3 1:CAS:528:DyaK2cXktVSntr8%3D
24. Sinko, P.J.: Martin's Physical Pharmacy and Pharmaceutical Sciences, 5th edn, pp. 278-279. Lippincott William's & Wilkins, Philadelphia (2006)
25. Higuchi, T., Connors, K.A.: Advances in Analytical Chemistry and Instrumentation, pp. 117-212. Interscience publishers, New York (1965)
26. K Uekama Y Horiuchi M Kikuchi F Hirayama T Ijitsu M Ueno 1988 Enhanced dissolution and oral bioavailability of α-tocopheryl esters by dimethyl-β-cyclodextrin complexation J. Incl. Phenom. 6 167 174 10.1007/BF00663049 1:CAS:528:DyaL1cXltFGqtrY%3D
27. Khan, K.A., Rhodes, C.T.: Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm. Acta Helv. 47, 594-607 (1972)
28. I Csóka E Csányi G Zapantis E Nagy A Fehér-Kiss G Horváth G Blazso I Eros 2005 In vitro and in vivo percutaneous absorption of topical dosage forms: case studies Int. J. Pharm. 291 11 19 10.1016/j.ijpharm.2004.07.038
29. E Nürnberg S Friess 1990 Poloxamers as structure-determining helping materials for brushable systems. 1. Report: Representation and Kennzeichung of tri-component-system from Poloxamer/paraffin/water (Poloxamere als strukturbestimmende Hilfstoffe für streichfähige Systeme. 1. Mitteilung: Darsellung und Kennzeichung von Drei-Komponentsystemen aus Poloxamer/Paraffin/Wasser) Pharm. Acta Helv. 65 105 112
30. VP Shah NW Tymes LA Yamamoto JP Skelly 1986 In vitro dissolution profile of transdermal nitroglycerin patches using paddle method Int. J. Pharm. 32 243 250 10.1016/0378-5173(86)90185-7 1:CAS:528:DyaL28XlvFOjur0%3D
31. T Caon ACO Costa MAL De Oliveira GA Micke CMO Simões 2010 Evaluation of the transdermal permeation of different paraben combinations through a pig ear skin model Int. J. Pharm. 391 1 6 10.1016/j.ijpharm.2010.02. 006 1:CAS:528:DC%2BC3cXltFCns70%3D
32. E Escribano AC Calpena J Queralt R Obach J Doménech 2003 Assessment of diclofenac permeation with different formulations: anti-inflammatory study of a selected formula Eur. J. Pharm. Sci. 19 203 210 10.1016/S0928-0987(03)00103-9 1:CAS:528:DC%2BD3sXls1Onu7c%3D
33. A Sevín P Özta D Senen Ü Han Ç Karaman N Tarimci M Kartal B Erdogan 2007 Effects of polyphenols on skin damage due to ultraviolet A rays: an experimental study on rats J. Eur. Acad. Dermatol. Venereol. 21 650 656
34. P Chowdhury S Panja S Chakravorti 2004 Photophysical behaviour of 4-(imidazole-1-yl) phenol and its complexation with beta-cyclodextrin in ground and excited states Spectrochim. Acta A Mol. Biomol. Spectrosc. 60 2295 2303 10.1016/j.saa.2003.12.003
35. T Loftsson D Hreinsdottir M Masson 2005 Evaluation of cyclodextrin solubilization of drugs Int. J. Pharm. 302 18 28 10.1016/j.ijpharm.2005.05.042 1:CAS:528:DC%2BD2MXpvVWju7w%3D
36. T Loftsson M Másson JF Sigurjónsdóttir 1999 Methods to enhance the complexation efficiency of cyclodextrins STP. Pharma. Sci. 9 237 242 1:CAS:528:DyaK1MXlsleiu7s%3D
37. KL Yap X Liu JC Thenmozhiyal PC Ho 2005 Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis Eur. J. Pharm. Sci. 25 49 56 10.1016/j.ejps.2005.01.021 1:CAS:528:DC%2BD2MXjs1Knu7c%3D
38. EMM Del Valle 2004 Cyclodextrins and their uses: a review Process Biochem. 39 1033 1046 10.1016/S0032-9592(03)00258-9
39. C Yuan Z Jin 2007 Aerobic biodegradability of hydroxypropyl-β- cyclodextrins in soil J. Incl. Phenom. Macrocycl. Chem. 58 345 351 10.1007/s10847-006-9281-0 1:CAS:528:DC%2BD2sXptl2isL4%3D
40. T Loftsson M Máasson ME Brewster 2003 Self-association of cyclodextrins and cyclodextrin complexes J. Pharm. Sci. 93 1091 1099 10.1002/jps.20047
41. HH Sigurdsson E Stefansson E Gudmundsdóttir T Eysteinsson M Thorsteinsdóttir T Loftsson 2005 Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration J. Contr. Rel. 102 255 262 10.1016/j.jconrel.2004.10.004 1:CAS:528:DC%2BD2MXktVGhsA%3D%3D
42. NN Buchi KPR Chowdary KVR Murthy V Satyanarayana AR Hayman G Becket 2005 Inclusion complexation and dissolution properties of nimesulide and meloxicam-hydroxypropyl-β-cyclodextrin binary systems J. Incl. Phenom. Macroc. Chem. 53 103 110 10.1007/s10847-005-1676-9
43. SM Badr-Eldin SA Elkheshen MM Ghorab 2008 Inclusion complexes of tadalafil with natural and chemically modified β-cyclodextrins. I: preparation and in vitro evaluation Eur. J. Pharm. Biopharm. 70 819 827 10.1016/j.ejpb.2008.06.024 1:CAS:528:DC%2BD1cXhtlagsL7F
44. CM Fernandes VM Teresa FJ Veiga 2002 Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds Eur. J. Pharm. Sci. 15 79 88 10.1016/S0928-0987(01)00208-1 1:CAS:528: DC%2BD38Xms1Glsg%3D%3D
45. KH Kim MJ Frank NL Henderson 1985 Applications of differential scanning calorimetry to the study of solid drug dispersions J. Pharm. Sci. 74 283 289 10.1002/jps.2600740312 1:CAS:528:DyaL2MXitV2hu7o%3D
46. SW Jun MS Kim JS Kim HJ Park S Lee JS Woo 2007 Preparation and characterization of simvastatin/hydroxypropyl- β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process Eur. J. Pharm. Biopharm. 66 413 421 10.1016/j.ejpb.2006.11.013 1:CAS:528:DC%2BD2sXlsFKmtbs%3D
47. C Rodríguez-Tenreiro C Alvarez-Lorenzo A Concheiro JJ Torres-Labandeira 2004 Characterization of cyclodextrin-carbopol interactions by DSC and FTIR J. Therm. Anal. Calorim. 77 403 411 10.1023/B:JTAN.0000038981. 30494.f4
48. JA Ryan 1986 Compressed pellet X-ray diffraction monitoring for optimization of crystallinity in lyophilized solids: imipenem: cilastatin sodium case J. Pharm. Sci. 75 805 807 10.1002/jps.2600750817 1:CAS:528: DyaL2sXptVSmtw%3D%3D
49. MD Veiga PJ Dìaz F Ahsan 1998 Interactions of griseofulvin with cyclodextrins in solid binary systems J. Pharm. Sci. 87 891 900 10.1021/js970233x 1:CAS:528:DyaK1cXjsl2htLo%3D
50. S Lin Y Kao 1989 Solid particulates of drug-β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique Int. J. Pharm. 56 249 259 10.1016/0378-5173(89)90022-7 1:CAS:528:DyaK3cXotl2rsA%3D%3D
51. J Moyano M Arias-Blanco J Ginés F Giordano 1997 Solid-state characterization of dissolution characteristics of gliclazide-β- cyclodextrin inclusion complexes Int. J. Pharm. 148 211 217 10.1016/S0378- 5173(96)04848-X 1:CAS:528:DyaK2sXjtF2hu7Y%3D
52. M Cirri C Rangoni F Maestrelli P Mura 2005 Development of fast-dissolving tablets of Flurbiprofen-cyclodextrin complexes Drug Dev. Ind. Pharm. 31 697 707 10.1080/03639040500253694 1:CAS:528:DC%2BD2MXhtV2gtLfN
53. JR Moyano JM Ginés MJ Arias AM Rabasco 1995 Study of the dissolution characteristics of oxazepam via complexation with β-cyclodextrin Int. J. Pharm. 114 95 102 10.1016/0378-5173(94)00220-Y 1:CAS:528:DyaK2MXivVKrtrg%3D
54. Banker, G.S., Rhodes, C.T.: Modern Pharmaceutics, 2nd edn, pp. 857-858. Marcel Dekker, New York (1990)
55. ID Nesseem 2001 Formulation and evaluation of itraconazole via liquid crystal for topical delivery system J. Pharmaceut. Biomed. Anal. 26 387 399 10.1016/S0731-7085(01)00414-9 1:CAS:528:DC%2BD3MXls1eitbo%3D
56. M Makai E Csányi Z Németh J Pálinkás I Erós 2003 Structure and drug release of lamellar liquid crystals containing glycerol Int. J. Pharm. 256 95 107 10.1016/S0378-5173(03)00066-8 1:CAS:528:DC%2BD3sXivVGjsbY%3D
57. Mittal, K.L.: Micellization, solubilization and microemulsions. In: Prince, L.M. (ed.) Micellization, Solubilization and Microemulsions, Vol. 1, pp. 45-54. Plenum Press, New York (1976)
58. Elworthy, P.H., Florence, A.T., Macfarlane, C.B.: Solubilization by Surface Active Agents, pp. 63-225. Chapman & Hall, London (1986)
59. K Kriwet CC Müller-Goymann 1993 Binary diclofenac diethylamine-water systems: micelles, vesicles and lyotropic liquid crystals Eur. J. Pharm. Biopharm. 39 234 238 1:CAS:528:DyaK2cXmtlyhsLY%3D
60. S Engström 1999 Cubid phases for studies of drug partition into a lipid bilayers Eur. J. Pharm. Sci. 8 243 254 10.1016/S0928-0987(99)00012-3
61. J Hadgraft 2001 Skin, the final frontier Int. J. Pharm. 224 1 18 10.1016/S0378-5173(01)00731-1 1:CAS:528:DC%2BD3MXmtVarur8%3D
62. Barry, B.W.: Dermatologic Formulations: Percutaneous Absorption, pp. 1-233. Marcel Dekker, New York (1983)
63. A El-Assasy II Soliman SF Farid 1997 Formulation and bioavailability of tiaprofenic acid suppositories Bull. Fac. Pharm. Cairo. Univ. 35 151 157 1:CAS:528:DyaK1cXitl2ntw%3D%3D
64. MA El-Nabarawi DI Nesseem AA Sleem 2003 Delivery and analgesic activity of tramadol from semisolid (topical) and solid (rectal) dosage forms Bull. Fac. Pharm. Cairo. Univ. 41 25 31 1:CAS:528:DC%2BD2cXhtVertbfI
65. M Kreilgaard 2002 Influence of microemulsions on cutaneous drug delivery Adv. Drug Del. Rev. 54 S77 S98 10.1016/S0169-409X(02)00116-3 1:CAS:528:DC%2BD38XpsVOhtrg%3D
66. ML Kripke 1991 Immunological effects of ultraviolet radiation J. Dermatol. 18 429 433 1:STN:280:DyaK387gsFGltA%3D%3D
67. CA Elmets PR Bergstresser 1982 Ultraviolet radiation effects on immune processes Photochem. Photobiol. 6 715 719 10.1111/j.1751-1097.1982.tb09494.x
68. M Yamawaki SK Katiyar CY Anderson KA Tubesing H Mukhtar CA Elmets 1997 Genetic variation in low-dose UV-induced suppression of contact hypersensitivity and in the skin photocarcinogenesis response J. Invest. Dermatol. 109 716 721 10.1111/1523-1747.ep12340683 1:CAS:528:DyaK1cXitFWjtg%3D%3D
69. ML Kripke 1984 Immunological unresponsiveness induced by ultraviolet radiation Immunol. Rev. 80 87 102 10.1111/j.1600-065X.1984.tb00496.x 1:STN:280:DyaL2M%2FivFWjuw%3D%3D
70. EG Jung 1991 Photocarcinogenesis in the Skin J. Dermatol. 18 1 10 1:STN:280:DyaK3M3mvVeksw%3D%3D
71. JM Rivas SE Ullrich 1994 The role of IL-4, IL-10 and TNF-alpha in the immune suppression induced by ultraviolet radiation J. Leukoc. Biol. 56 769 775 1:CAS:528:DyaK2MXis1Kgt7s%3D
72. B Eberlein-König C Jäger B Przybilla 1998 Ultraviolet B radiation-induced production of interleukin 1alpha and interleukin 6 in human squamous carcinoma cell line is wavelength-dependent and can be inhibited by pharmacological agents Br. J. Dermatol. 139 415 421 10.1046/j.1365-2133.1998. 02404.x
73. NA Soter 1990 Acute effects of ultraviolet radiation on the skin Semin. Dermatol. 9 11 15 1:STN:280:DyaK3czms1CmsA%3D%3D
74. DS Snyder 1975 Cutaneous effects of topical indomethacin, an inhibitor of prostaglandin synthesis, on UV damaged skin J. Invest. Dermatol. 64 322 325 10.1111/1523-1747.ep12512265 1:CAS:528:DyaE2MXkslaisb4%3D
75. K Kuwamoto H Miyauchi-Hashimoto K Tanaka N Eguchi T Inui Y Urade T Horio 2000 Possible involvement of enhanced prostaglandin E2 production on the photosensitivity in xeroderma pigmentosum group A model mice J. Invest. Dermatol. 114 241 246 10.1046/j.1523-1747.2000.0883x.x 1:CAS:528: DC%2BD3cXktlWgtLY%3D